{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T08:45:01Z","timestamp":1792313101352,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s41669-025-00561-7","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T10:31:50Z","timestamp":1737628310000},"page":"487-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5384-4918","authenticated-orcid":false,"given":"Panagiotis","family":"Papantoniou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4103-4181","authenticated-orcid":false,"given":"Nikolaos","family":"Maniadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"561_CR1","unstructured":"World Health Organization. Obesity and overweight. 2024. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 08 Jul 2024."},{"key":"561_CR2","unstructured":"World Health Organization. WHO European regional obesity report. 2022. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/353747\/9789289057738-eng.pdf?sequence=1. Accessed 6 Jul 2024"},{"key":"561_CR3","unstructured":"World Health Organization. The Global Health Observatory. Prevalence of obesity among adults, BMI \u2265 30 (age-standardised estimate) (%). 2024. Available from: https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/prevalence-of-obesity-among-adults-bmi--30-(age-standardized-estimate)-(-). Accessed 15 Jul 2024"},{"key":"561_CR4","unstructured":"Greek Ministry of Health. National action against childhood obesity. 2023. Available from: https:\/\/www.moh.gov.gr\/articles\/ministry\/grafeio-typoy\/press-releases\/11342-ethniko-programma-prolhpshs-kai-katapolemhshs-ths-paxysarkias-enhlikwn. Accessed 1 Aug 2024"},{"issue":"9","key":"561_CR5","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.2105\/AJPH.2016.303395","volume":"106","author":"A Hruby","year":"2016","unstructured":"Hruby A, Manson JE, Qi L, Malik VS, Rimm EB, Sun Q, et al. Determinants and consequences of obesity. Am J Public Health. 2016;106(9):1656\u201362. https:\/\/doi.org\/10.2105\/AJPH.2016.303395.","journal-title":"Am J Public Health"},{"key":"561_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/2327-6924.12423","author":"SM Fruh","year":"2017","unstructured":"Fruh SM. Obesity: risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract. 2017. https:\/\/doi.org\/10.1002\/2327-6924.12423.","journal-title":"J Am Assoc Nurse Pract"},{"issue":"S1","key":"561_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14404","volume":"23","author":"S Sarma","year":"2021","unstructured":"Sarma S, Sockalingam S, Dash S. Obesity as a multisystem disease: trends in obesity rates and obesity-related complications. Diabetes Obes Metab. 2021;23(S1):3\u201316. https:\/\/doi.org\/10.1111\/dom.14404.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"561_CR8","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1007\/s11695-020-05057-0","volume":"31","author":"S Erridge","year":"2021","unstructured":"Erridge S, Moussa O, McIntyre C, Hariri A, Tolley N, Kotecha B, et al. Obstructive sleep apnea in obese patients: a UK population analysis. Obes Surg. 2021;31(5):1986\u201393. https:\/\/doi.org\/10.1007\/s11695-020-05057-0.","journal-title":"Obes Surg"},{"key":"561_CR9","doi-asserted-by":"publisher","unstructured":"Global Burden of Disease. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(24)00056-7.","DOI":"10.1016\/S0140-6736(24)00056-7"},{"issue":"6","key":"561_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0167-6296(97)00030-6","volume":"16","author":"S Anand","year":"1997","unstructured":"Anand S, Hanson K. Disability-adjusted life years: a critical review. J Health Econ. 1997;16(6):685\u2013702. https:\/\/doi.org\/10.1016\/S0167-6296(97)00030-6.","journal-title":"J Health Econ"},{"issue":"9669","key":"561_CR11","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","volume":"373","author":"Prospective Studies Collaboration","year":"2009","unstructured":"Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(09)60318-4.","journal-title":"Lancet"},{"issue":"2","key":"561_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S2213-8587(14)70229-3","volume":"3","author":"SA Grover","year":"2015","unstructured":"Grover SA, Kaouache M, Rempel P, Joseph L, Dawes M, Lau DC, et al. Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study. Lancet Diabetes Endocrinol. 2015;3(2):114\u201322. https:\/\/doi.org\/10.1016\/S2213-8587(14)70229-3.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"561_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40273-016-0389-9","volume":"34","author":"M Karimi","year":"2016","unstructured":"Karimi M, Brazier J. Health, health-related quality of life, and quality of life: what is the difference? Pharmacoeconomics. 2016;34:645\u20139. https:\/\/doi.org\/10.1007\/s40273-016-0389-9.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"561_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/sj.ijo.0803688","volume":"32","author":"F Corica","year":"2008","unstructured":"Corica F, Corsonello A, Apolone G, Mannucci E, Lucchetti M, Bonfiglio C, et al. Metabolic syndrome, psychological status and quality of life in obesity: the QUOVADIS Study. Int J Obes. 2008;32(1):185\u201391. https:\/\/doi.org\/10.1038\/sj.ijo.0803688.","journal-title":"Int J Obes"},{"issue":"5","key":"561_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000334136","volume":"4","author":"TI Karlsen","year":"2011","unstructured":"Karlsen TI, Tveit\u00e5 EK, Natvig GK, Tonstad S, Hjelmes\u00e6th J. Validity of the SF-36 in patients with morbid obesity. Obes Facts. 2011;4(5):346\u201351. https:\/\/doi.org\/10.1159\/000334136.","journal-title":"Obes Facts"},{"key":"561_CR16","unstructured":"World Obesity. World Obesity Atlas 2023. 2023. Available from: https:\/\/www.worldobesityday.org\/resources\/entry\/world-obesity-atlas-2023. Accessed 5 Jun 2024."},{"issue":"25 Pt B","key":"561_CR17","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","volume":"63","author":"MD Jensen","year":"2014","unstructured":"Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985\u20133023. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.004.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"561_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/j.1467-789X.2010.00740.x","volume":"11","author":"JCM Barte","year":"2010","unstructured":"Barte JCM, Ter Bogt NCW, Bogers RP, Teixeira PJ, Blissmer B, Mori TA, et al. Maintenance of weight loss after lifestyle interventions for overweight and obesity, a systematic review. Obes Rev. 2010;11(12):899\u2013906. https:\/\/doi.org\/10.1111\/j.1467-789X.2010.00740.x.","journal-title":"Obes Rev"},{"key":"561_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.physbeh.2013.07.009","volume":"120","author":"CN Ochner","year":"2013","unstructured":"Ochner CN, Barrios DM, Lee CD, Pi-Sunyer FX. Biological mechanisms that promote weight regain following weight loss in obese humans. Physiol Behav. 2013;120:106\u201313. https:\/\/doi.org\/10.1016\/j.physbeh.2013.07.009.","journal-title":"Physiol Behav"},{"issue":"6","key":"561_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000442721","volume":"8","author":"V Yumuk","year":"2015","unstructured":"Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402\u201324. https:\/\/doi.org\/10.1159\/000442721.","journal-title":"Obes Facts"},{"key":"561_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.vhri.2017.09.002","volume":"16","author":"JN Yfantopoulos","year":"2018","unstructured":"Yfantopoulos JN, Chantzaras A. Drug policy in Greece. Value Health Reg Issues. 2018;16:66\u201373. https:\/\/doi.org\/10.1016\/j.vhri.2017.09.002.","journal-title":"Value Health Reg Issues."},{"issue":"2","key":"561_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomised clinical trial. JAMA. 2022;327(2):138\u201350. https:\/\/doi.org\/10.1001\/jama.2021.23619.","journal-title":"JAMA"},{"key":"561_CR23","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"issue":"4","key":"561_CR24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/dom.14929","volume":"25","author":"J Azuri","year":"2023","unstructured":"Azuri J, Hammerman A, Aboalhasan E, Sluckis B, Arbel R. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: a value for money analysis. Diabetes Obes Metab. 2023;25(4):961\u20134. https:\/\/doi.org\/10.1111\/dom.14929.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"561_CR25","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s13300-023-01498-y","volume":"14","author":"RR Mody","year":"2023","unstructured":"Mody RR, Meyer KL, Ward JM, O\u2019Day KB. Cost per patient achieving treatment targets and number needed to treat with tirzepatide versus semaglutide 1 mg in patients with type 2 diabetes in the United States. Diabetes Ther. 2023;14(12):2045\u201355. https:\/\/doi.org\/10.1007\/s13300-023-01498-y.","journal-title":"Diabetes Ther."},{"key":"561_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01456-5","author":"AV Olivieri","year":"2024","unstructured":"Olivieri AV, Muratov S, Larsen S, Luckevich M, Chan K, Lamotte M, et al. Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective. Int J Obes. 2024. https:\/\/doi.org\/10.1038\/s41366-024-01456-5.","journal-title":"Int J Obes"},{"issue":"1","key":"561_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13098-024-00970-7","volume":"16","author":"L Silva Miguel","year":"2024","unstructured":"Silva Miguel L, Soares M, Olivieri A, Sampaio F, Lamotte M, Shukla S, et al. Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal. Diabetol Metab Syndr. 2024;16(1):97. https:\/\/doi.org\/10.1186\/s13098-024-00970-7.","journal-title":"Diabetol Metab Syndr"},{"key":"561_CR28","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00228-024-03755-w","volume":"80","author":"AS Asiabar","year":"2024","unstructured":"Asiabar AS, Rezaei MA, Jafarzadeh D, et al. The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review. Eur J Clin Pharmacol. 2024;80:1857\u201370. https:\/\/doi.org\/10.1007\/s00228-024-03755-w.","journal-title":"Eur J Clin Pharmacol"},{"key":"561_CR29","doi-asserted-by":"publisher","first-page":"1254398","DOI":"10.3389\/fendo.2023.1254398","volume":"14","author":"Y Xue","year":"2023","unstructured":"Xue Y, Zou H, Ruan Z, Chen X, Lai Y, Yao D, et al. Pharmacoeconomic evaluation of anti-obesity drugs for chronic weight management: a systematic review of literature. Front Endocrinol (Lausanne). 2023;14:1254398. https:\/\/doi.org\/10.3389\/fendo.2023.1254398.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"6","key":"561_CR30","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/oby.23796","volume":"31","author":"J Azuri","year":"2023","unstructured":"Azuri J, Hammerman A, Aboalhasan E, Sluckis B, Arbel R. Liraglutide versus semaglutide for weight reduction\u2014a cost needed to treat analysis. Obesity (Silver Spring). 2023;31(6):1510\u20133. https:\/\/doi.org\/10.1002\/oby.23796.","journal-title":"Obesity (Silver Spring)"},{"key":"561_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10198-011-0374-3","volume":"13","author":"G van de Wetering","year":"2012","unstructured":"van de Wetering G, Woertman WH, Adang EM. Time to incorporate time in cost-effectiveness analysis. Eur J Health Econ. 2012;13:223\u20136. https:\/\/doi.org\/10.1007\/s10198-011-0374-3.","journal-title":"Eur J Health Econ"},{"key":"561_CR32","unstructured":"Government Gazette. FEK 1100 15\/02\/2024. 2024. Available from: https:\/\/www.moh.gov.gr\/articles\/times-farmakwn\/ypoyrgikes-apofaseis-agoranomikes-diatakseis\/5556-diatakseis-timologhshs-farmakwn-g5-a-oik-90552-fek-3890-b-2016. Accessed 02 Jun 2024."},{"key":"561_CR33","unstructured":"Government Gazette. FEK 40977 24\/09\/2024. 2024. Available from: https:\/\/www.moh.gov.gr\/articles\/times-farmakwn\/deltia-timwn\/12751-orthh-epanalhpsh-laquo-deltio-timwn-farmakwn-anthrwpinhs-xrhshs-me-enswmatwsh-dioikhtikwn-metabolwn-kai-anaprosarmoghs-timwn-gia-logoys-dhmosias-ygeias-kai-symplhrwmatiko-deltio-timwn-farmakwn-anthrwpinhs-xrhshs-katopin-aithmatos-meiwshs-timhs-raquo. Accessed 07 Oct 2024."},{"key":"561_CR34","unstructured":"Government Gazette. FEK B\u2019 4045\/17-11-2017. 2017. Available from: https:\/\/fsax.gr\/wp-content\/uploads\/2020\/edapy\/5fek4045b.17.11.2017.pdf. Accessed 02 Jun 2024."},{"issue":"5","key":"561_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ijcp.12142","volume":"67","author":"L Citrome","year":"2013","unstructured":"Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407\u201311. https:\/\/doi.org\/10.1111\/ijcp.12142.","journal-title":"Int J Clin Pract"},{"key":"561_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: OUP Oxford; 2006."},{"issue":"4","key":"561_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2019.12.008","volume":"23","author":"M Dabbous","year":"2020","unstructured":"Dabbous M, Chachoua L, Caban A, Toumi M. Managed entry agreements: policy analysis from the European perspective. Value Health. 2020;23(4):425\u201333. https:\/\/doi.org\/10.1016\/j.jval.2019.12.008.","journal-title":"Value Health."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00561-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00561-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00561-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:58:59Z","timestamp":1745855939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00561-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00561-7","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"9 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Part of the article processing charge (APC) fees were covered by the Special Account for Research Grants of the University of West Attica, Athens, Greece.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Panagiotis Papantoniou and Nikolaos Maniadakis have made equal and substantial contributions to this study, from its conceptualization and design to the meticulous analysis of data and its meaningful interpretation and revision.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contributions"}},{"value":"Professor Maniadakis and Dr. Papantoniou have no conflicts of interest directly relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data analysis for this study was conducted using Microsoft Excel. The cost-of-control model is available as an electronic supplementary material.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The data supporting the findings of this study are derived from publicly available sources and referenced within the manuscript. Clinical efficacy data were sourced from the STEP-8 trial, while cost inputs were obtained from the official drug price list published by the Greek Ministry of Health and government Gazette, as detailed in the references. For any further information or data queries, please contact the corresponding author.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}